Edward C. Saltzman - 12 Sep 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Christine Ring, as Attorney-in-Fact for Edward C. Saltzman
Issuer symbol
NRIX
Transactions as of
12 Sep 2022
Net transactions value
$0
Form type
4
Filing time
14 Sep 2022, 16:25:30 UTC
Next filing
04 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 12 Sep 2022 Common Stock 50,000 $16.29 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 1/36 of the total shares monthly beginning October 12, 2022 until the option is fully vested on September 12, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.